CD21(lo) B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma

Immune checkpoint inhibitor (ICI) therapy increases the risk of immune-related adverse events (irAEs). In particular, combination checkpoint blockade (CCB) targeting inhibitory CTLA-4 and PD-1 receptors could lead to irAEs at a higher rate than ICI monotherapy. Management of irAEs is important while...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Kenichi, Konishi, Tatsuya, Ochi, Toshiki, Watanabe, Ryuta, Noda, Terutaka, Fukumoto, Tetsuya, Miura, Noriyoshi, Miyauchi, Yuki, Kikugawa, Tadahiko, Takenaka, Katsuto, Saika, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225635/
https://www.ncbi.nlm.nih.gov/pubmed/35743673
http://dx.doi.org/10.3390/jpm12060888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225635/
https://www.ncbi.nlm.nih.gov/pubmed/35743673
http://dx.doi.org/10.3390/jpm12060888

Ejemplares similares